Skip to main content
NVDA+0.55%AAPL-1.15%GOOGL-1.29%MSFT-0.75%AMZN-1.79%TSM-1.08%SPCX-2.05%META+0.76%AVGO-0.71%TSLA+0.05%SKHY-0.08%BRK-B-0.02%LLY+0.40%MU+0.51%JPM-1.41%WMT-0.34%AMD+1.69%V-0.41%XOM+1.82%JNJ-1.15%ASMLa-1.17%0700.HK+1.90%MA-0.61%INTC+0.93%ABBV-0.08%1398.HK-2.09%CSCO+0.45%CVX+1.55%BAC-0.41%ORCL-1.11%COST-1.27%KO-1.01%DELL+3.11%CAT-0.73%HSBA.L-1.91%0005.HK-3.21%PG+0.21%UNH-1.67%LRCX-2.49%AP2d-2.39%AMAT-1.33%1816.HK-0.46%3988.HK-2.13%NFLX-2.63%GE-2.59%MS-2.63%0857.HK+0.60%HD-1.49%PM-0.16%0939.HK-2.83%USDJPY+0.98%NZDUSD-0.93%CHFJPY+0.75%USDTHB+0.72%GBPJPY+0.67%GBPNZD+0.66%CADJPY+0.64%NZDCHF-0.62%NZDCAD-0.59%AUDUSD-0.58%EURUSD-0.49%EURJPY+0.47%EURNZD+0.45%AUDJPY+0.42%GBPTRY+0.41%NOKJPY+0.40%PLNJPY+0.38%AUDNZD+0.36%USDCAD+0.34%GBPHKD+0.32%USDCHF+0.31%NZDMXN-0.30%GBPMXN-0.28%GBPUSD-0.28%GBPAUD+0.28%SGDJPY+0.27%USDTRY+0.25%AUDCHF-0.25%AUDCAD-0.21%USDSEK+0.21%USDSGD+0.19%EURGBP-0.18%EURCAD-0.17%USDILS+0.16%EURCHF-0.16%EURSEK+0.15%EURSGD+0.14%CHFNOK-0.13%NZDSGD-0.13%EURCZK+0.12%EURAUD+0.10%GBPSGD+0.10%USDPLN+0.09%GBPZAR-0.09%AUDDKK-0.09%USDCNH+0.08%USDNOK+0.07%AUDNOK-0.07%GBPCAD+0.06%AUDSGD+0.06%NZDJPY+0.05%USDDKK+0.05%EURZAR-0.05%EURHKD-0.05%CADCHF-0.04%USDMXN+0.04%USDCOP-0.04%EURPLN+0.03%USDHKD+0.02%GBPCHF+0.01%USDZAR+0.01%CHFSGD-0.01%EURNOK+0.01%EURDKK-0.01%CHFSEK0.00%EURCNH0.00%USOIL+2.68%UKOIL+1.78%W1+1.52%XNGUSD+1.30%SUGAR-1.10%COFFEE-1.01%C1+0.87%COCOA-0.86%S1+0.82%HG1+0.39%XAUUSD-0.38%GAUUSD-0.38%BTCUSD-2.79%ETHUSD-4.17%USDTUSD-0.03%XRPUSD-2.53%SOLUSD-3.46%TRXUSDT-0.44%ZECUSDT-4.31%DOGEUSD-2.41%XMRUSDT+0.57%LINKUSD-2.70%XLMUSD+0.08%BCHUSDT-1.61%UNIUSD-3.53%LTCUSD-2.81%HBARUSDT-0.52%TONUSD+26.79%SUIUSD-2.90%TAOUSDT-3.72%AAVEUSD-2.66%DOTUSDT-2.31%ICPUSDT-7.29%ONDOUSDT-3.74%WLDUSDT-1.82%ARBUSDT+3.88%ATOMUSDT-1.85%JUPUSDT-4.72%INJUSDT-10.07%STXUSDT-3.49%FETUSDT-4.47%PYTHUSDT-4.62%TIAUSDT-6.43%SEIUSDT-2.47%IMXUSDT-1.81%OPUSDT-2.68%GRTUSDT-4.45%WIFUSDT-5.33%POLUSDT+0.01%IOTAUSDT-5.93%AXSUSDT-3.52%FARTCOINUSDT-2.30%EOSUSDT-4.57%DYDXUSDT-6.40%ORDIUSDT-2.31%GALAUSDT-2.06%NOTUSDT-0.18%RONINUSDT-11.07%NVDA+0.55%AAPL-1.15%GOOGL-1.29%MSFT-0.75%AMZN-1.79%TSM-1.08%SPCX-2.05%META+0.76%AVGO-0.71%TSLA+0.05%SKHY-0.08%BRK-B-0.02%LLY+0.40%MU+0.51%JPM-1.41%WMT-0.34%AMD+1.69%V-0.41%XOM+1.82%JNJ-1.15%ASMLa-1.17%0700.HK+1.90%MA-0.61%INTC+0.93%ABBV-0.08%1398.HK-2.09%CSCO+0.45%CVX+1.55%BAC-0.41%ORCL-1.11%COST-1.27%KO-1.01%DELL+3.11%CAT-0.73%HSBA.L-1.91%0005.HK-3.21%PG+0.21%UNH-1.67%LRCX-2.49%AP2d-2.39%AMAT-1.33%1816.HK-0.46%3988.HK-2.13%NFLX-2.63%GE-2.59%MS-2.63%0857.HK+0.60%HD-1.49%PM-0.16%0939.HK-2.83%USDJPY+0.98%NZDUSD-0.93%CHFJPY+0.75%USDTHB+0.72%GBPJPY+0.67%GBPNZD+0.66%CADJPY+0.64%NZDCHF-0.62%NZDCAD-0.59%AUDUSD-0.58%EURUSD-0.49%EURJPY+0.47%EURNZD+0.45%AUDJPY+0.42%GBPTRY+0.41%NOKJPY+0.40%PLNJPY+0.38%AUDNZD+0.36%USDCAD+0.34%GBPHKD+0.32%USDCHF+0.31%NZDMXN-0.30%GBPMXN-0.28%GBPUSD-0.28%GBPAUD+0.28%SGDJPY+0.27%USDTRY+0.25%AUDCHF-0.25%AUDCAD-0.21%USDSEK+0.21%USDSGD+0.19%EURGBP-0.18%EURCAD-0.17%USDILS+0.16%EURCHF-0.16%EURSEK+0.15%EURSGD+0.14%CHFNOK-0.13%NZDSGD-0.13%EURCZK+0.12%EURAUD+0.10%GBPSGD+0.10%USDPLN+0.09%GBPZAR-0.09%AUDDKK-0.09%USDCNH+0.08%USDNOK+0.07%AUDNOK-0.07%GBPCAD+0.06%AUDSGD+0.06%NZDJPY+0.05%USDDKK+0.05%EURZAR-0.05%EURHKD-0.05%CADCHF-0.04%USDMXN+0.04%USDCOP-0.04%EURPLN+0.03%USDHKD+0.02%GBPCHF+0.01%USDZAR+0.01%CHFSGD-0.01%EURNOK+0.01%EURDKK-0.01%CHFSEK0.00%EURCNH0.00%USOIL+2.68%UKOIL+1.78%W1+1.52%XNGUSD+1.30%SUGAR-1.10%COFFEE-1.01%C1+0.87%COCOA-0.86%S1+0.82%HG1+0.39%XAUUSD-0.38%GAUUSD-0.38%BTCUSD-2.79%ETHUSD-4.17%USDTUSD-0.03%XRPUSD-2.53%SOLUSD-3.46%TRXUSDT-0.44%ZECUSDT-4.31%DOGEUSD-2.41%XMRUSDT+0.57%LINKUSD-2.70%XLMUSD+0.08%BCHUSDT-1.61%UNIUSD-3.53%LTCUSD-2.81%HBARUSDT-0.52%TONUSD+26.79%SUIUSD-2.90%TAOUSDT-3.72%AAVEUSD-2.66%DOTUSDT-2.31%ICPUSDT-7.29%ONDOUSDT-3.74%WLDUSDT-1.82%ARBUSDT+3.88%ATOMUSDT-1.85%JUPUSDT-4.72%INJUSDT-10.07%STXUSDT-3.49%FETUSDT-4.47%PYTHUSDT-4.62%TIAUSDT-6.43%SEIUSDT-2.47%IMXUSDT-1.81%OPUSDT-2.68%GRTUSDT-4.45%WIFUSDT-5.33%POLUSDT+0.01%IOTAUSDT-5.93%AXSUSDT-3.52%FARTCOINUSDT-2.30%EOSUSDT-4.57%DYDXUSDT-6.40%ORDIUSDT-2.31%GALAUSDT-2.06%NOTUSDT-0.18%RONINUSDT-11.07%
AP

Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ • Healthcare

$33.64
+$2.01 (+6.4%)
Market open

Last close at September 14, 2026 at 20:00 UTC

Open$31.84
Previous Close$33.64
Day Range$31.57 - $33.96
Avg. Volume (3M)3.7M
Market Cap$3.6B
52 Week Range
$10.83$41.14
Next EarningsIn 51 daysNov 5, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$152M
EPS (TTM)
-$1.41
ROA (TTM)
-57.49%
Current Ratio
12.12

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+3.2%Q1 2026-$0.3
-8.8%Q2 2026-$0.37
-8.1%Q3 2026-$0.39
Next

Nov 5

in 51 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -8.1%

Amylyx Pharmaceuticals’ earnings missed consensus in the second fiscal quarter of 2026, based on preliminary results reported August 6, 2026, with EPS of -$0.39 trailing the -$0.36 estimate by -$0.03. The company posted GAAP net income of roughly -$43.4 million, down about 5% year over year from -$41.4 million a year ago, while GAAP operating income was around -$45.7 million. Cash flow from operations was negative at roughly -$31.4 million for the quarter. Amylyx remains a clinical-stage biopharmaceutical company focused on AMX0035 in amyotrophic lateral sclerosis and other neurodegenerative conditions. For the next period, consensus calls for EPS of -$0.38 on revenue of $59,429.00.

View full earnings history

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a NASDAQ-listed healthcare company in biotechnology that develops therapies for amyotrophic lateral sclerosis and other neurodegenerative conditions. The company operates as a clinical-stage biopharmaceutical firm, with its work centered on AMX0035, a named therapy candidate that anchors its development pipeline and research focus.

Name
Amylyx Pharmaceuticals, Inc.
CEO
Joshua Cohen
Website
amylyx.com
Industry
Healthcare
Year Founded
2013
Employees
136

Today's Snapshot

AI-generated

AMLX opened 1.2% lower at 33.22, while its sector was flat.

Trading Volume

Below 10d avg (1.4M)

348.5K

vs S&P 500 Today

Strong Underperformance

-3.19%

Updated: September 15, 2026 at 15:00 UTC

Technical Indicators

5 Buy2 Neutral1 Sell
AMLX reads as a strong buy on the basis of a robust trend and supportive longer-term averages, while near-term indicators are mixed. ADX is strong, signaling a committed trend, and although 10-period averages sit above the market, the 50/100/200-period moving averages are well below the current price and remain bullish. Momentum shows divergence with stochastic and Williams %R indicating buying interest while MACD and RSI are neutral. Volatility is elevated and OBV does not confirm strength, and the pivot sits near the price. Technical takeaway: Strong buy bias driven by the multi-period uptrend.
All signals
  • EMA (5 indicators)$19.33 - $33.16
    Buy
  • RSI (14)55.49
    Neutral
  • Stochastic %K (14, 3, 3)17.48
    Buy
  • MACD Level (12, 26)1.79
    Neutral

Peers & Related Assets

RLAYRelay Therapeutics, Inc.
$19.06+1.0%
PGENPrecigen, Inc.
$6.850.0%
SNDXSyndax Pharmaceuticals, Inc.
$18.35+0.9%
INBXInhibrx Biosciences Inc.
$110.47+1.1%
ORICORIC Pharmaceuticals, Inc.
$12.65+5.1%
SANASana Biotechnology, Inc.
$3.2+2.2%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.